Form 8-K - Current report:
SEC Accession No. 0001193125-25-131525
Filing Date
2025-05-30
Accepted
2025-05-30 08:30:30
Documents
12
Period of Report
2025-05-29
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d908206d8k.htm   iXBRL 8-K 30589
  Complete submission text file 0001193125-25-131525.txt   144452

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20250529.xsd EX-101.SCH 2859
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20250529_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20250529_pre.xml EX-101.PRE 11267
14 EXTRACTED XBRL INSTANCE DOCUMENT d908206d8k_htm.xml XML 3629
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 251006651
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)